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Purpose: The aim of this study was to evaluate the
efﬁcacy and safety of a ﬁxed-dose combination of mon-
telukast and levocetirizine in patients with perennial
allergic rhinitis with mild to moderate asthma com-
pared with the efﬁcacy and safety of montelukast
alone.
Methods: This study was a 4-week, randomized,
multicenter, double-blind, Phase III trial. After a 1-
week placebo run-in period, the subjects were random-
ized to receive montelukast (10 mg/day, n = 112) or
montelukast (10 mg/day)/levocetirizine (5 mg/day)
(n = 116) treatment for 4 weeks. The primary efﬁcacy
end point was mean daytime nasal symptom score.
Other efﬁcacy end points included mean nighttime
nasal symptom score, mean composite symptom score,
overall assessment of allergic rhinitis by both subjects
and physicians, forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), FEV1/FVC,
asthma control test score, and the frequency of rescue
medication used during the treatment period.
Findings: Of 333 patients screened for this study,
228 eligible patients were randomized to treatment.
The mean (SD) age of patients was 43.32 (15.02) years,
and two thirds of subjects were female (66.67%). The
demographic characteristics were similar between the
treatment groups. Compared with the montelukast
group, the montelukast/levocetirizine group reported
signiﬁcant reductions in mean daytime nasal symptom
score (least squares mean [SE] of combination vs mon-
telukast, 0.98 [0.06] vs 0.81 [0.06]; P = 0.045). For
all other allergic rhinitis efﬁcacy end points, theJuly 2018montelukast/levocetirizine group showed greater
improvement than the montelukast group. Similar
results were observed in overall assessment scores and
in FEV1, FVC, FEV1/FVC, and asthma control test
score changes from baseline for the 2 treatment groups.
Montelukast/levocetirizine was well tolerated, and the
safety proﬁle was similar to that observed in the monte-
lukast group.
Implications: The ﬁxed-dose combination of mon-
telukast and levocetirizine was effective and safe in
treating perennial allergic rhinitis in patients with
asthma compared with montelukast alone. Clinical-
Trials.gov identiﬁer: NCT02552667. (Clin Ther.
2018;40:10961107) © 2018 The Authors. Published
by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Key words: allergic rhinitis, asthma, clinical trial,
ﬁxed-dose combination, levocetirizine, montelukast.TAGGEDH1INTRODUCTIONTAGGEDEND
Rhinitis is an inﬂammation of the mucous lining of the
nose, accompanied by symptoms that include rhinor-
rhea, sneezing, itching, nasal obstruction, and post-
nasal drip. Allergic rhinitis, an immunoglobulin
Emediated allergic inﬂammatory response caused by
exposure to allergens, accounts for more than one half
of all rhinitis cases and is observed in 10% to 50% of
the world population. Speciﬁcally, in Asia, the1097
Clinical Therapeuticsincidence of allergic rhinitis is 10% to 40% in adults
and 10% to 46% in children.1
Asthma is a chronic inﬂammatory disorder of the
lower airway. Approximately 300 million people
worldwide are estimated to have asthma, and its preva-
lence ranges from 1% to 18%, depending on the coun-
try surveyed.2 Allergic rhinitis and asthma have long
been regarded as separate clinical manifestations of
upper and lower respiratory tract diseases, respectively.
However, recent advances in research have shown that
allergic respiratory diseases are not restricted to speciﬁc
areas, such as the nasal cavity or bronchi, but are pres-
ent throughout the respiratory system; they appear as a
wide range of clinical disorders, including rhinitis and
asthma, which are closely related to each other epide-
miologically, clinically, and pathophysiologically.38
The features of airway hypersensitivity, as well as
early- and late-phase allergic reactions, can be present
in both the nose and lungs simultaneously. In patients
with rhinitis without asthma, methacholine inhalation
induces lower respiratory tract responses similar to
those observed in patients with asthma. Several clinical
and experimental studies have reported that anatomic
and physiological similarities exist between the nose
and the lung, and that a decrease in nasal function can
exert a negative inﬂuence on lung function.912 The
development of 1 disease may precede the other, and
the 2 diseases are induced by the same triggers. Thus,
they frequently manifest symptoms simultaneously.13
This concept is referred to as “united airway dis-
ease,” “one airway one disease,” or “allergic
rhinobronchitis.”38 On the basis of this concept,
international treatment guidelines, including Allergic
Rhinitis and its Impact on Asthma, recommend that
clinicians check for the presence of asthma in
patients with allergic rhinitis, and vice versa, so that
an integrated therapeutic approach for the 2 dis-
eases can be appropriately applied.8
Many mediators, cytokines, and growth factors pro-
duced by various cells are involved in the chronic
inﬂammation seen in rhinitis and asthma. They con-
tribute to airway hyperreactivity and repetitive symp-
toms, including wheezing, dyspnea, chest tightness,
and coughing. Among these, cysteinyl leukotrienes are
one of the important mediators responsible for upper
(rhinitis) and lower (asthma) airway diseases.14 These
mediators contribute to the manifestations of asthma,
including airway edema, smooth muscle contraction,
and inﬂammatory cell inﬁltration. In addition,1098cysteinyl leukotrienes induce increased blood ﬂow and
mucus oversecretion, which elicits nasal obstruction in
allergic rhinitis. Montelukast effectively relieves
asthma symptoms and improves lung function via the
inhibition of cysteinyl leukotriene receptor 1.15 It also
reduces daytime and nighttime nasal (ie, late-phase)
symptoms of patients with rhinitis.1619
Histamine is a major mediator of allergic rhinitis via
stimulation of H1 receptors in the upper airway. Levo-
cetirizine is a nonsedating, oral antihistamine that is
widely used in alleviating early-phase symptoms of
allergic rhinitis, including sneezing, nasal itchiness, and
rhinorrhea. However, the effect of antihistamine on
nasal obstruction is minimal.20,21
Theoretically, the therapeutic effectiveness of treat-
ing nasal symptoms may be enhanced by a combina-
tion of levocetirizine and montelukast, thus affecting
inhibition of both early- and late-phase reactions in
allergic rhinitis. The aim of the present study was to
compare the efﬁcacy and safety of a ﬁxed-dose com-
bination (FDC) of montelukast (10 mg/day) and lev-
ocetirizine (5 mg/day) versus those of montelukast
(5 mg/day) monotherapy in subjects with perennial
allergic rhinitis and mild to moderate asthma.TAGGEDH1PATIENTS ANDMETHODSTAGGEDEND
Study Patients
Patients with mild to moderate asthma and allergic
rhinitis, aged >15 years, were recruited to the study if
they met 1 of the following criteria: (1) they were newly
diagnosed with asthma after reversibility testing
(12% increase in forced expiratory volume in 1 sec-
ond [FEV1] after inhaling a short-acting beta-agonist)
or bronchial challenge testing (methacholine or manni-
tol hyperresponsiveness); (2) they were taking montelu-
kast (10 mg/day) as monotherapy for asthma treatment
for at least 4 weeks before screening (step II according
to the Global Initiative for Asthma guideline); or (3)
they required step-up with add-on montelukast therapy
(10 mg/day) from inhaled corticosteroids (ICS) (step III
according to the Global Initiative for Asthma guideline)
to treat partially controlled asthma with stable doses of
ICS for >4 weeks before screening. All subjects had at
least 2 of the following symptoms: rhinorrhea, nasal
obstruction, sneezing, and itching. They also had posi-
tive skin prick test or speciﬁc immunoglobulin E test
results for at least 1 of 10 perennial allergens: house
dust, Dermatophagoides farinae, DermatophagoidesVolume 40 Number 7
M.-K. Kim et al.pteronyssinus, cat dander, dog dander, Alternaria,
Aspergillus, Cladosporium, Penicillium, and cockroach
mix.
Exclusion criteria included nonallergic rhinitis (eg,
vasomotor, infectious, drug related), lung diseases (eg,
pulmonary tuberculosis, chronic obstructive pulmo-
nary disease), and upper respiratory tract infection
within 3 weeks and nasal surgery within 3 months
before visit 1. Patients on a stable dose of ICS were eli-
gible based on the inclusion criteria. Other medications
for allergic rhinitis, conjunctivitis, and asthma were
not allowed during the placebo run-in and treatment
periods, including: H1 antihistamines; intranasal cro-
molyn; nedocromil; anticholinergics; decongestants;
oral, parenteral, ophthalmic, inhaled, and intranasal
corticosteroids; beta-agonists; and antileukotrienes.
Study Design
This analysis was a multicenter, double-blind, ran-
domized Phase III study conducted at 22 centers in the
Republic of Korea from October 2014 to July 2015.
Written informed consent was obtained from all sub-
jects before the study participation. The protocol was
approved by the institutional review boards of each
institution, and the study was registered at www.clini
caltrials.gov (NCT02552667). The study adhered to
the tenets of the Declaration of Helsinki.
This study was conducted over 5 weeks (a 1-week
placebo run-in period and a 4-week treatment period).
The subjects who voluntarily participated in this clini-
cal trial were screened based on set inclusion/exclusion
criteria at the ﬁrst visit (visit 1). After screening, a pla-
cebo was administered to those patients eligible for
study participation once daily during the 1-week run-
in period. At visit 2, daytime nasal symptom scores
recorded in a daily diary during the run-in period were
assessed, and the subjects who met the criteria
described in the assessment section were randomly
assigned to either the montelukast (10 mg/day) group
(n = 112) or the montelukast (10 mg/day)/levocetirizine
(5 mg/day) group (n = 116) with 1:1 allocation. Ran-
domization was stratiﬁed on the basis of ICS use during
the run-in period. The subjects took the study drug
once every evening throughout the treatment period
and visited the study centers at 2-week intervals (visits
3 and 4) for safety and efﬁcacy assessments.
During the study, the treatment groups were double-
blinded by using matched placebos of the study drugs.
The FDCs of montelukast and levocetirizine and itsJuly 2018placebo capsule were both beige-colored and were sup-
plied by Hanmi Pharmaceutical Co (Seoul, Republic of
Korea). The placebo capsule contained cellulose and
lactose and had the identical size, shape, and weight as
the FDC capsule. Montelukast was provided as beige-
colored, ﬁlm-coated tablet, which was produced by
MSD Korea (Seoul, Republic of Korea). Its placebo
was composed of mannitol, cellulose, and starch and
was produced in the same shape by Hanmi Pharmaceu-
tical Co.Assessment Methods
Allergic Rhinitis Symptom Score
The participants completed diary card entries for the
entire 5-week study duration. Throughout the 1-week
run-in and 4-week treatment periods, rhinitis symp-
toms were evaluated based on the daily diary card
entries for both daytime (assessed in the evening) and
nighttime (assessed in the morning) symptoms, using a
4-point scale (see the Supplemental Table in the online
version at doi:10.1016/j.clinthera.2018.04.021). Day-
time nasal symptoms included rhinorrhea, nasal
obstruction, sneezing, and itching, each scored from 0
to 3 (0 = none; 1 =mild; 2 = moderate; and 3 = severe).
Nighttime nasal symptoms included nasal obstruction
awakening (0 = none; 1 =mild; 2 = moderate;
3 = severe), difﬁculty getting to sleep (0 = not at all;
1 = little; 2 = moderate; 3 = severe), and nighttime
awakening (0 = not at all; 1 = once; 2 = more than once;
3 = awake all night).
Subjects were enrolled at visit 2 when their recorded
daytime nasal symptom scores for at least 4 days dur-
ing the 1-week placebo run-in period and the average
of their total daytime nasal symptom scores were 6 of
the maximum total score of 12.Overall Assessment of Allergic Rhinitis
At visit 4, overall allergic rhinitis symptoms were
evaluated separately by the subjects and the physicians
and were compared with those of visit 2. The following
scoring system was used: 0 = very much improved,
1 =much improved, 2 = slightly improved, 3 = no
change, 4 = slightly worse, 5 = much worse, and
6 = very much worse.Spirometry
FEV1, forced vital capacity (FVC), and FEV1/FVC
percentages were measured at visits 2 and 4. The use of1099
Clinical Therapeuticsrescue medication was prohibited for at least 6 hours
before spirometric measurement.
Asthma Control Test
Subjects completed the asthma control test (ACT)
questionnaire at visits 2 and 4.
Rescue Medication
A rescue medication (120 mg/puff of salbutamol sul-
fate*) was administered as needed. The subjects were
asked to record in their daily diaries the number of
times that they used rescue medication.Efﬁcacy End Points
The primary efﬁcacy end point was the change in
mean daytime nasal symptom score (MDNSS) from
baseline to the treatment period (visits 34). The
daytime nasal symptom score was the mean of 4
individual symptom scores for rhinorrhea, nasal
obstruction, sneezing, and itching. The MDNSS was
measured by averaging all daily daytime nasal symp-
tom scores during the placebo run-in period for base-
line and during each 2-week treatment period (visits
23 and 34).
The secondary allergic rhinitis efﬁcacy end points
were mean nighttime nasal symptom score (MNNSS),
mean composite symptom score (MCSS), and overall
assessment scores recorded by both the subjects and
the physicians. The MNNSS was measured by averag-
ing all daily nighttime nasal symptom scores for nasal
obstruction awakening, difﬁculty getting to sleep, and
nighttime awakening, and MCSS was calculated by
averaging the MDNSS and the MNNSS.
The other secondary efﬁcacy end points were the
changes in FEV1, FVC, FEV1/FVC percentages, and
ACT scores from visit 2 to visit 4, as well as the total
and mean daily frequency of rescue medication use per
subject.Safety Assessment
Safety assessments included treatment-emergent
adverse events (TEAEs), physical and laboratory
examinations, vital signs, and 12-lead ECGs. TEAEs
were evaluated by assessing the incidence and severity
at every visit, and their relationship to the study drug
was evaluated according to the physician’s judgment.* Trademark: Ventolin

Evohaler (GlaxoSmithKline,
Research Triangle Park, North Carolina).
1100Laboratory tests, including hematology, biochemistry,
urinalysis, and 12-lead ECGs, were conducted at ran-
domization and the end of the study.
Statistical Analysis
Efﬁcacy end points were analyzed by using the
intention-to-treat approach. Efﬁcacy data analyses
were performed on all randomized subjects who
had received at least 1 dose of the double-blind
study drug and had had at least 1 measurement
recorded both at baseline and during the treatment
period for the primary efﬁcacy end point (full analy-
sis set). Safety analyses were performed on the
safety analysis set, which included all randomized
patients who had taken at least 1 dose of the inves-
tigational product.
Diary-based efﬁcacy end points were analyzed as
their mean changes from baseline, but any missing val-
ues on the diary were not imputed for statistical analy-
sis. An ANCOVA model was applied to determine the
efﬁcacy end points (excluding overall assessment and
frequency of rescue medication use), with baseline data
as a covariate. Two-sample independent t tests were
used to analyze the overall assessment scores of allergic
rhinitis made by the subjects and the physicians, as
well as the frequency of rescue medication used
between the treatment groups. The incidence of adverse
events was compared by using either Pearson's x2 test
or Fisher's exact test. All tests were 2-sided at the 5%
signiﬁcance level. SAS version 9.4 (SAS Institute, Inc,
Cary, North Carolina) was used for all statistical anal-
yses.
The difference in change from baseline in MDNSS
between the treatment groups was determined as
0.23, with an SD of 0.6, a power of 80%, and a sig-
niﬁcance level of 5%. This approach yielded a sample
size of 107 subjects per group. Considering a dropout
rate of 5%, a sample size of 226 (113 per treatment
group) was calculated.TAGGEDH1RESULTSTAGGEDEND
Patient Disposition and Baseline Characteristics
Of the 333 subjects screened, 228 were randomized
to treatment, and 209 completed the study. A total of
19 subjects dropped out; the most common reason for
dropout was withdrawal of consent (6 subjects)
(Figure 1). The number of subjects included in the full
analysis set was 210, and their baseline characteristicsVolume 40 Number 7
(N = 333)
(N = 228)
(n = 116)
M + L
Figure 1. Subject disposition. L = levocetirizine 5 mg; M =montelukast 10 mg.
M.-K. Kim et al.are summarized in Table I. The mean age of all subjects
was 43.32 (15.02) years, and two thirds of them were
female (66.67%). The mean duration of asthma was
72.30 (86.77) months, and most of the subjects had
mild asthma (84.29%). There were no statistically sig-
niﬁcant differences in baseline characteristics, except
that the frequency of rescue medication used during
the placebo run-in period was signiﬁcantly higher in
the montelukast/levocetirizine group than in the mon-
telukast group.
Efﬁcacy Evaluation
Allergic Rhinitis
The change from baseline in allergic rhinitis symp-
tom scores for the 2 treatment groups is shown in
Figure 2 and Table II. The montelukast/levocetirizine
group achieved statistically signiﬁcant improvement in
change from baseline in MDNSS (least squares mean
[SE]) during the 2-week treatment period (visits 34)
compared with that of the montelukast group (0.98
[0.06] vs 0.81 [0.06]; P = 0.0450).
The montelukast/levocetirizine group exhibited a
statistically signiﬁcant improvement in sneezing com-
pared with the montelukast alone group, althoughJuly 2018rhinorrhea, itching, and nasal obstruction were mar-
ginally improved (P = 0.060 to 0.387). The combina-
tion group scores also revealed greater improvement in
MDNSS, excluding nasal obstruction, compared with
that of the montelukast group (P = 0.0194). However,
there were no statistically signiﬁcant differences
between the treatment groups in terms of MNNSS and
MCSS.
The subjects’ overall assessment score (mean [SD])
was 1.83 (1.05) for the montelukast/levocetirizine
group and 1.99 (1.06) for the montelukast group; the
physicians’ overall assessment score was 1.80 (1.07)
for the combination group and 1.89 (0.96) for the
montelukast group. There were no signiﬁcant differen-
ces between the treatment groups (P = 0.2740 and
P = 0.5017, respectively).Asthma
The change in FEV1 from baseline to the end of the
study (least squares mean [SE]) was 0.00 (0.23) L for
the montelukast/levocetirizine group, which was simi-
lar to the result of 0.01 (0.16) L for the montelukast
group (P = 0.6848).1101
Table I. Baseline characteristics of the study patients (full analysis set). Data are given as mean (SD) unless oth-
erwise indicated.
Characteristic
M + L
(n = 107)
M
(n = 103)
Total
(N = 210)
P
Age, y 42.55 (14.35) 44.13 (15.71) 43.32 (15.02) 0.4488*
Sex
Male 35 (32.71%) 35 (33.98%) 70 (33.33%) 0.8452y
Female 72 (67.29%) 68 (66.02%) 140 (66.67%)
Height, cm 163.26 (8.52) 162.09 (8.22) 162.68 (8.37) 0.3120*
Weight, kg 63.47 (13.03) 63.90 (12.84) 63.68 (12.91) 0.8142*
Asthma status
Duration of asthma, mo 77.35 (94.94) 67.05 (77.50) 72.30 (86.77) 0.3892*
Asthma severity
Mild 88 (82.24%) 89 (86.41%) 177 (84.29%) 0.4071y
Moderate 19 (17.76%) 14 (13.59%) 33(15.71%)
Inhaled corticosteroid use 47 (43.93%) 49 (47.57%) 96 (45.71%) 0.5958y
Montelukast administration 44 (41.12%) 43 (41.75%) 87 (41.43%) 0.9266y
Newly diagnosed asthma 16 (14.95%) 11 (10.68%) 27 (12.86%) 0.3550y
Baseline efﬁcacy measures related to rhinitisz
MDNSS 1.89 (0.34) 1.89 (0.32) 1.89 (0.33) 0.9095x
MDNSS excluding nasal obstruction 1.86 (0.38) 1.84 (0.39) 1.85 (0.38) 0.7018x
MNNSS 1.33 (0.59) 1.34 (0.64) 1.34 (0.61) 0.8232*
MCSS 1.61 (0.38) 1.62 (0.39) 1.61 (0.38) 0.8972*
Baseline efﬁcacy measures related to asthma
FEV1 2.62 (0.74) 2.57 (0.73) 2.60 (0.74) 0.5361
x
FVC 3.36 (0.85) 3.37 (0.86) 3.36 (0.85) 0.9339x
FEV1/FVC, % 78.28 (10.90) 76.46 (10.03) 77.4 (10.5) 0.1776
x
ACT total score 17.88 (4.39) 18.73 (4.00) 18.30 (4.21) 0.1568x
Daily rescue medication use 0.72 (1.03) 0.38 (0.61) 0.55 (0.86) 0.0237x
ACT = asthma control test; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; L = levocetirizine 5 mg;
M =montelukast 10 mg; MCSS =mean composite symptom score; MDNSS =mean daytime nasal symptom score;
MNNSS =mean nighttime nasal symptom score.
* P values are based on 2-sample independent t test.
y P values are based on Pearson's x2 test.
zMean score during the placebo run-in period; all symptoms were scored on a scale from 0 to 3.
x P values are based on Wilcoxon’s rank sum test.
Clinical TherapeuticsThe change in FVC, FEV1/FVC, and ACT scores
from baseline was also similar between the 2 treatment
groups (Table III). Both the total and mean daily fre-
quencies of rescue medication use during the treatment
period were signiﬁcantly higher for the montelukast/
levocetirizine group than for the montelukast group
(total use [mean (SD)], 15.62 [27.15] vs 8.51 [21.06],
P = 0.035; mean daily usage [mean (SD)], 0.53 [0.93]
vs 0.29 [0.74], P = 0.039).1102Safety Evaluation
The safety analysis set included 224 patients. During
the study period, 19 subjects (16.67%) in the montelu-
kast/levocetirizine group and 18 subjects (16.36%) in
the montelukast group experienced TEAEs (Table IV).
Common adverse events (1% incidence) in the monte-
lukast/levocetirizine group were reported as “upper
respiratory tract infection” in 4 subjects (3.51%), “naso-
pharyngitis” in 3 subjects (2.63%), “gastrointestinalVolume 40 Number 7
Figure 2. Change from baseline in mean daytime
nasal symptom score (MDNSS). L = lev-
ocetirizine 5 mg; LS = least squares;
M =montelukast 10 mg. *P < 0.05
M + L versus M at the indicated time
point based on ANCOVA, with baseline
data as covariate.
Table II. Change from baseline in allergic rhinitis symptom
analysis set.
Symptom Scorey
M+ L
(n = 107)
MDNSS 0.98 (0.06) 
Rhinorrhea 0.91 (0.06) 
Nasal obstruction 0.91 (0.07) 
Sneezing 1.08 (0.06) 
Pruritus 1.02 (0.07) 
MDNSS excluding nasal obstruction 1.00 (0.06) 
MNNSS 0.61 (0.05) 
Nasal obstruction on wakening 0.64 (0.06) 
Difﬁculty getting to sleep 0.61 (0.06) 
Nighttime awakening 0.56 (0.06) 
MCSS 0.79 (0.05) 
L = levocetirizine 5 mg; M =montelukast 10 mg; MCSS =mean com
tom score; MNNSS =mean nighttime nasal symptom score.
* Reported as least squares mean (SE). Least squares mean, SE,
data as covariate.
yMean score during blinded treatment period  Mean score durin
scale from 0 to 3.
M.-K. Kim et al.
July 2018disorder” in 2 subjects (1.75%), and “tonsillitis” in 2
subjects (1.75%). In the montelukast group, “upper
respiratory tract infection” in 4 subjects (3.64%), “pru-
ritus” in 2 subjects (1.82%), and “tonsillitis” in 1 subject
(0.91%) were reported. Adverse drug reactions were
reported by 2 subjects (1.75%) in the montelukast/levo-
cetirizine group and by 2 subjects (1.82%) in the monte-
lukast group. For serious adverse events, 1 subject in the
montelukast/levocetirizine group reported “gastric can-
cer,” and 1 subject in the montelukast group reported
“cholelithiasis.” Neither of these was considered to be
related to the study drugs. No signiﬁcant differences
were found in TEAEs, adverse drug reactions, or serious
adverse events between the treatment groups. There
were no laboratory adverse events, and no clinically
meaningful changes in vital signs, ECGs, or physical
examination results reported in this study, and these pro-
ﬁles were comparable between the 2 treatment groups.TAGGEDH1 ISCUSSIONTAGGEDEND
The primary purpose of the present study was to show the
efﬁcacy of an FDC of montelukast and levocetirizine on
allergic rhinitis in patients with asthma. The montelukast/score during the treatment period (weeks 34)*: full
M
(n = 103) Difference (95% CI) P
0.81 (0.06) 0.17 (0.33 to 0.00) 0.0450
0.77 (0.07) 0.14 (0.32 to 0.04) 0.1349
0.83 (0.07) 0.09 (0.28 to 0.11) 0.3871
0.81 (0.07) 0.26 (0.45 to 0.08) 0.0050
0.84 (0.07) 0.18 (0.37 to 0.01) 0.0610
0.81 (0.06) 0.19 (0.36 to 0.03) 0.0194
0.53 (0.05) 0.08 (0.23 to 0.07) 0.2924
0.57 (0.07) 0.07 (0.25 to 0.11) 0.4363
0.51 (0.06) 0.10 (0.26 to 0.06) 0.2085
0.49 (0.06) 0.07 (0.23 to 0.10) 0.4257
0.67 (0.05) 0.12 (0.27 to 0.02) 0.0995
posite symptom score; MDNSS =mean daytime nasal symp-
95% CIs, and P values are based on ANCOVA with baseline
g the placebo run-in period; all symptoms were scored on a
1103
Table III. Change from baseline in lung function parameters and asthma control test (ACT) total score*: full
analysis set.
Variable
M + L
(n = 105y)
M
(n = 103) Difference (95% CI) P
FEV1, L 0.00 (0.02) 0.01 (0.02) 0.01 (0.06 to 0.04) 0.6848
FVC, L 0.00 (0.02) 0.02 (0.02) 0.01 (0.07 to 0.05) 0.6632
FEV1/FVC, % 0.04 (0.37) 0.00 (0.38) 0.04 (1.09 to 1.02) 0.9459
ACT total score 2.08 (0.25)z 2.42 (0.26) 0.33 (1.05 to 0.38) 0.3604
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; L = levocetirizine 5 mg; M =montelukast 10 mg.
* Reported as least squares mean (SE). Least squares mean, SE, 95% CIs, and P values are based on ANCOVA, with baseline as
covariate.
yThe data analysis set included all randomized subjects who had received at least 1 dose of the double-blind study drug and
had both baseline and postbaseline measurements for the lung function parameters.
zThe data analysis set of ACT total score involved 106 subjects in the M + L group.
Table IV. Summary of treatment-emergent adverse events (TEAEs)*: safety analysis set.
Variable
M + L
(n = 114)
M
(n = 110) P
Any TEAEs 19 (16.67) 18 (16.36) 0.9513y
Severity 0.3761z
Mild 16 (14.04) 12 (10.91)
Moderate 2 (1.75) 5 (4.55)
Severe 1 (0.88) 1 (0.91)
Adverse drug reactions 2 (1.75) 2 (1.82) 1.0000z
Serious adverse events 1 (0.88) 1 (0.91) 1.0000z
Gastric cancer 1 (0.88) 0 (0.00)
Cholelithiasis 0 (0.00) 1 (0.91)
Common TEAEs
Upper respiratory tract infection 4 (3.51) 4 (3.64) 1.0000z
Nasopharyngitis 3 (2.63) 0 (0.00) 0.2469z
Tonsillitis 2 (1.75) 1 (0.91) 1.0000z
Gastrointestinal disorder 2 (1.75) 0 (0.00) 0.4979z
Pruritus 0 (0.00) 2 (1.82) 0.2400z
L = levocetirizine 5 mg; M =montelukast 10 mg.
* Reported as number (percentage). Adverse events occurring in safety analysis set in any treatment group.
y P values are based on Pearson's x2 test.
z P values are based on Fisher's exact test.
Clinical Therapeuticslevocetirizine group exhibited a statistically signiﬁcant
improvement in change from baseline in the primary end
point, MDNSS, compared with that of the montelukast
group. In addition, the montelukast/levocetirizine group
exhibited numerical improvement in all allergic rhinitis1104efﬁcacy end points, including each symptom score of
MDNSS, compared with those of the montelukast alone
group, and in sneezing score and MDNSS, excluding
nasal obstruction, which showed a statistically signiﬁcant
difference between the groups (Table II).Volume 40 Number 7
M.-K. Kim et al.Similar results have been presented in previous clini-
cal studies that evaluated the efﬁcacy of a montelukast
and antihistamine combination in treating patients with
allergic rhinitis.2226 Meltzer et al23 reported that the
co-administration of montelukast and loratadine signiﬁ-
cantly improved the daytime nasal symptoms score (P <
0.001) compared with that after placebo administration
and each agent alone, with a safety proﬁle comparable
to that of the placebo or each agent alone. They con-
cluded that the combination of montelukast and lorata-
dine provides clinical beneﬁts against prevalent
respiratory diseases, because asthma and allergic rhinitis
comorbidities are common.23 In addition, Ciebiada et al
reported that a combination of montelukast and either
desloratadine or levocetirizine is more effective than
monotherapy for persistent allergic rhinitis.25
Allergic rhinitis and asthma have long been regarded
and treated as separate disorders.3 Recent advances in
research, however, have shown that links between the
2 diseases exist, resulting in frequent coexistence of the
diseases in the same patients.4
Asthma is reportedly prevalent in 10% to 40% of
patients with allergic rhinitis, which is higher than the
prevalence rate in healthy populations, and that 80%
of patients with asthma have allergic rhinitis.1,8,26,27 In
another study, the incidence of asthma was reported to
be >10-fold higher in patients with allergic rhinitis
than in those without it.28 Moreover, the severity of
rhinitis has been associated with the severity of coexist-
ing asthma.29 Speciﬁcally, rhinitis not only worsens
asthma prognosis but also lowers a patient’s quality of
life by limiting daily activities and reducing efﬁciency
at work.27,30 Rhinitis in asthma can also contribute to
more frequent asthma exacerbations and relapses, as
well as hospitalization and emergency department
visits.3134
These associations can be explained through the ana-
tomic, physiological, and immunologic mechanisms of
the upper and lower airways. These airways share ana-
tomic similarities, including continuity of the basement
membranes, pseudostratiﬁed ciliated columnar epithelia,
mucus transport, serous glands, nasal epithelial cells,
sympathetic and parasympathetic nerve distribution,
and responses to the circadian rhythm. In addition, the
same stimuli, including nonspeciﬁc irritants such as cold
air and cigarette smoke, as well as allergens, induce
inﬂammatory responses in both airways. They also share
the same inﬂammatory mediators released from mast
cells, eosinophils, basophils, and Th2 lymphocytes.July 2018Nasal eosinophilic inﬂammation is present in asthma
patients with or without nasal symptoms.1012
All of this information indicates that rhinitis and
asthma are manifestations of either the same or similar
inﬂammatory processes that develop in the common
respiratory tract tissue. It is therefore important that
rhinitis and asthma not be evaluated as separate disor-
ders, and both need to be treated when they coexist.
In the present study, the end points related to
asthma were evaluated as secondary end points because
the 4-week treatment period was too short for asthma
evaluation. The changes in lung function parameters
(FEV1, FVC, and FEV1/FVC) and ACT scores from
baseline were similar between the montelukast/levoce-
tirizine group and the montelukast group. However,
both the total and mean daily frequencies of rescue
medication use during the treatment period were higher
in the montelukast/levocetirizine group than in the
montelukast group. It is assumed that these differences
between the groups were attributed to the baseline
characteristics rather than treatment effects. During the
run-in period, the mean daily frequency of rescue medi-
cation use was statistically signiﬁcantly higher in the
montelukast/levocetirizine group than in the montelu-
kast group. This difference in the baseline might have
affected the outcome. In the correlation analysis
between the frequencies of rescue medication use dur-
ing the run-in period and during the treatment period,
there was a positive correlation between the frequency
of rescue medication use during the run-in and treat-
ment periods (R = 0.764). This ﬁnding means that the
subjects who had a tendency to use rescue medication
frequently during the run-in period were more likely to
continue using rescue medicine in the treatment period.
A potential limitation of the present study is the short
duration of assessment of asthma symptom (4 weeks).
Generally, the recommended duration of asthma assess-
ment in clinical trials for controller medication is at least
6 months.34 In future studies, we will consider a longer
assessment period so that the effects of combination ther-
apy on asthma can be examined in greater depth.TAGGEDH1CONCLUSIONSTAGGEDEND
This study shows that although both montelukast and
levocetirizine are widely used therapeutic agents,
administered alone or in combination, greater
improvement in allergic rhinitis symptoms occurred
with the FDC of montelukast and levocetirizine than1105
Clinical Therapeuticswith montelukast alone. Moreover, the combination
therapy was well tolerated and demonstrated an
acceptable safety proﬁle, similar to that observed with
montelukast. We therefore fully expect that the FDC of
montelukast and levocetirizine will provide signiﬁ-
cantly improved rhinitis outcomes in patients with
allergic rhinitis and asthma.TAGGEDH1 CKNOWLEDGMENTS TAGGEDEND
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Clinical TherapeuticsTAGGEDH1SUPPLEMENTARY MATERIALSupplemental Table. Ratings for the nasal symptoms.
Daytime nasal symptoms Nighttime nasal symptoms
Score Rhinorrhea
Nasal
obstruction Sneezing Itching
Nasal obstruction
awakening
Difﬁculty
getting to sleep
Nighttime
awakening
0 None (symptoms not noticeable) None Not at all Not at all
1 Mild
(mild intermittent symptoms that do not interfere
with daily activities)
Mild Little Once
2 Moderate
(moderate symptoms that interfere slightly with daily
activities)
Moderate Moderate More than
once
3 Severe
(very severe symptoms that interfere greatly with
daily activities)
Severe Severe Awake all
night
Each symptom was scored using a 4-point scale (0 to 3). Daytime nasal symptoms were assessed in the evening and nighttime
nasal symptoms were assessed in the morning every day.1107.e1 Volume 40 Number 7
